Updated:
BIOASTER
BIOASTER was founded in 2012 as a non-profit technological research institute focused on microbiology and infectious diseases. Alexandre Moulin serves as CEO...
Overview
BIOASTER was founded in 2012 as a non-profit technological research institute focused on microbiology and infectious diseases. Alexandre Moulin serves as CEO and Philippe Archinard as President. The institute originated from collaboration among the French Government, Institut Pasteur, Lyonbiopôle and several industrial partners. BIOASTER pursues early-stage research projects in applied microbiology. It structures work through collaborative agreements rather than traditional fund commitments or direct equity investments. Confirmed partners include Sanofi, bioMérieux, Danone Nutricia Research and Boehringer Ingelheim. Operations span France with primary activity in Europe. The institute employs researchers across its Lyon headquarters and Paris office. It belongs to the FIT network of French technological research institutes and maintains membership in LyonBiopôle and the BEAM Alliance. No recent operational events from the last 24 months appear in available records. BIOASTER functions as a scientific cooperation foundation with governance tied to its founding public and private partners. This structure separates its research mandate from standard endowment or family-office investment vehicles.
General information
Firm type
Endowment / Foundation
Year founded
2012
Location
Region
Europe
Country
France
City
Lyon
Corporate office
40 avenue Tony Garnier, 69007 Lyon, France
Additional offices
Paris, France
Principals
Alexandre Moulin
CEO
Philippe Archinard
President
Sector focus
Frequently asked questions
Who runs investment decisions at BIOASTER?
Alexandre Moulin serves as CEO. Philippe Archinard serves as President. Decisions center on collaborative research projects rather than financial portfolio allocation.
How does BIOASTER source proprietary deal flow?
BIOASTER sources projects through its founding partners including Institut Pasteur, Sanofi and bioMérieux. It also draws from membership in LyonBiopôle and the BEAM Alliance.
Does BIOASTER participate in fund commitments or only direct deals?
BIOASTER engages in collaborative research agreements with public and private partners. It does not make fund commitments or direct equity investments.
What investment stages does BIOASTER typically target?
BIOASTER targets early-stage research in microbiology and infectious diseases. Its work focuses on applied technology development rather than commercial investment stages.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: